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Abstract
In prion diseases, the cellular form of the prion protein, PrP
C, undergoes a conformational conversion to the infectious
isoform, PrP
Sc. PrP
C associates with lipid rafts through its glycosyl-phosphatidylinositol (GPI) anchor and a region in its N-
terminal domain which also binds to heparan sulfate proteoglycans (HSPGs). We show that heparin displaces PrP
C from rafts
and promotes its endocytosis, suggesting that heparin competes with an endogenous raft-resident HSPG for binding to
PrP
C. We then utilised a transmembrane-anchored form of PrP (PrP-TM), which is targeted to rafts solely by its N-terminal
domain, to show that both heparin and phosphatidylinositol-specific phospholipase C can inhibit its association with
detergent-resistant rafts, implying that a GPI-anchored HSPG targets PrP
C to rafts. Depletion of the major neuronal GPI-
anchored HSPG, glypican-1, significantly reduced the raft association of PrP-TM and displaced PrP
C from rafts, promoting its
endocytosis. Glypican-1 and PrP
C colocalised on the cell surface and both PrP
C and PrP
Sc co-immunoprecipitated with
glypican-1. Critically, treatment of scrapie-infected N2a cells with glypican-1 siRNA significantly reduced PrP
Sc formation. In
contrast, depletion of glypican-1 did not alter the inhibitory effect of PrP
C on the b-secretase cleavage of the Alzheimer’s
amyloid precursor protein. These data indicate that glypican-1 is a novel cellular cofactor for prion conversion and we
propose that it acts as a scaffold facilitating the interaction of PrP
C and PrP
Sc in lipid rafts.
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Introduction
Creutzfeldt-Jakob (CJD) disease of humans, bovine spongiform
encephalopathy of cattle and scrapie of sheep are all examples of
prion diseases. These diseases propagate through the misfolding of
the normal cellular form of the prion protein (PrP
C) into the
disease-associated isoform (PrP
Sc) [1]. The conversion of PrP
C to
PrP
Sc is accompanied by a large increase in the b-sheet content of
the protein and a propensity to aggregate into larger macromo-
lecular structures. PrP
C is post-translationally modified with a
glycosyl-phosphatidylinositol (GPI) anchor attached to the C-
terminus. The GPI anchor facilitates the association of PrP
C with
cholesterol- and sphingolipid-rich membrane microdomains,
termed lipid rafts (reviewed in [2]). Lipid rafts are characterised
biochemically by their resistance to solubilisation with detergents,
such as Triton X-100, at low temperature, with the resulting
detergent-resistant membranes (DRMs) enriched in raft resident
proteins and lipids [3]. PrP
C also associates with lipid rafts by
virtue of raft targeting determinants within its N-terminal domain
[4,5]. However, the identity of the raft interacting partner(s) for the
N-terminal domain of PrP
C remains unknown.
A number of studies suggest that the formation of PrP
Sc takes
place in lipid rafts. For example, PrP
Sc, like PrP
C, is present in
DRMs isolated from cultured cells [6,7]. Furthermore, when the
GPI anchor of PrP
C is replaced by a transmembrane anchor, the
protein redistributes to non-raft regions of the plasma membrane
and no conversion occurs [7,8]. In addition, depletion of cellular
cholesterol levels to disrupt lipid rafts leads to a reduction in the
PrP
Sc-load in infected cell culture models [8–10].
The presence of prion conversion cofactors in a given subcellular
location may rationalise why a particular site is favoured for
conversion [11]. Of these potential cofactors, there is evidence
linking proteoglycans and their glycosaminoglycan (GAG) side
chains to PrP
C metabolism [12]. Sulfated GAGs, including heparan
sulfate, were identified as constituents of PrP
Sc plaques in the brains
of CJD, Gerstmann-Straussler-Scheinker disease and kuru cases, as
well as in hamster brains infected with scrapie [13,14]. The N-
terminal half of PrP
C has been shown to bind heparan sulfate
[15,16],with the basicresiduesattheextreme N-terminusofmature
PrP
C constituting a particularly strong site of interaction [17–19].
GAGs stimulated the endocytosis of chicken PrP
C [15] and heparin
reduced the level of cell surface human PrP
C by an unknown
mechanism [17]. Furthermore, the incorporation of PrP
Sc into
Chinese Hamster Ovary cells required endogenous GAG expres-
sion [20] and heparan sulfate acted as a cellular receptor for prion
rods in neuroblastoma cells [21]. However, despite all these
observations, the identity of the cellular heparan sulfate involved
in the interaction with PrP
C and/or PrP
Sc, whether it is lipid raft-
associated andinvolved in the conformational conversion ofPrP
C to
PrP
Sc remain to be determined.
In the current study we show that heparin promotes the
endocytosis of mammalian PrP
C and displaces it from lipid rafts,
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heparan sulfate proteoglycan (HSPG) for binding to PrP
C.W e
then utilised a transmembrane-anchored construct of PrP, PrP-
TM [22], which associates with DRMs solely through the raft
targeting determinant in its N-terminal domain [5], to identify the
GPI-anchored HSPG glypican-1 as a molecule that targets PrP
C to
detergent-resistant lipid rafts. In addition, we show that glypican-1
directly interacts with both PrP
C and PrP
Sc and that depletion of
glypican-1 in scrapie-infected murine neuroblastoma N2a (ScN2a)
cells inhibits the formation of PrP
Sc.
Results
Heparin stimulates the endocytosis of PrP
C and displaces
it from lipid rafts
To investigate whether heparin promotes the endocytosis of
mammalian PrP
C, and to determine the mechanism involved, we
utilised human neuroblastoma SH-SY5Y cells stably expressing
murine PrP
C (tagged with the 3F4 antibody epitope) and an
established endocytosis assay [23,24]. It should be noted that the
SH-SY5Y cells do not express detectable levels of endogenous
PrP
C (see Fig. 1E) as reported previously [19,25,26]. In the
endocytosis assay, plasma membrane proteins are selectively
labelled using a cell-impermeable biotin reagent, thus allowing
their distinction from proteins either in the secretory pathway or
already endocytosed. Cells were then incubated with heparin for
1 h at 37uC and subsequently treated with trypsin to remove
residual cell surface PrP
C prior to lysis. Any PrP
C endocytosed
during the course of the experiment is protected from trypsin
digestion. In the absence of heparin, negligible (4%) cell surface
PrP
C was endocytosed, whereas heparin stimulated the endocy-
tosis of PrP
C in a dose-dependent manner, with 77% internalised
by 100 mM heparin in 1 h (Fig. 1A and B).
Cu
2+ ions stimulate the clathrin-dependent endocytosis of PrP
C
by a mechanism which is initiated by the protein dissociating from
lipid rafts [24]. Therefore, we determined whether heparin could
likewise displace PrP
C from lipid rafts. Cells were first surface
biotinylated and then incubated with heparin before homogeni-
sation in the presence of Triton X-100 followed by buoyant
sucrose density gradient centrifugation. Consistent with previous
reports [5,24], PrP
C in cells incubated in the absence of heparin
resided almost exclusively at the 5%/30% sucrose interface in the
DRM fractions containing the raft-associated protein, flotillin-1
(Fig. 1C). However, in cells incubated with heparin, a significant
amount (37%) of PrP
C redistributed to detergent-soluble fractions
of the plasma membrane isolated at the bottom of the sucrose
gradient containing the transferrin receptor (TfR, Fig. 1C and D).
To determine whether the heparin treatment had any effect on
other aspects of PrP
C metabolism, we investigated the effect of the
1 h heparin treatment on the expression and shedding of PrP
C in
untransfected and PrP
C-transfected SH-SY5Y cells (Fig. 1E).
Endogenous PrP
C expression in untransfected SH-SY5Y cells
remained undetectable following heparin treatment (Fig. 1E). In
the SH-SY5Y cells transfected with PrP
C, 1 h heparin treatment
led to 19.5% reduction in the total cellular amount of PrP
C (Fig. 1E
and F) which may be attributable to its degradation following
endocytosis. No PrP
C was detected in concentrated conditioned
media in the presence or absence of heparin treatment (data not
shown). Together, these data indicate that the addition of heparin
to cells for 1 h does not increase the expression or shedding of
PrP
C but stimulates the endocytosis of mammalian PrP
C by its
lateral displacement from detergent-resistant lipid rafts into
detergent-soluble regions of the plasma membrane. From this,
we hypothesised that the lateral movement of PrP
C from rafts may
occur as exogenous heparin competes with an endogenous raft-
resident HSPG for binding to PrP
C.
PrP-TM interacts with DRMs through association with the
GPI-anchored HSPG glypican-1
To test this hypothesis we employed a transmembrane-anchored
construct of PrP (PrP-TM) in which the GPI anchor signal sequence
of murine PrP is replaced with the transmembrane and cytosolic
domains of the non-raft protein angiotensin converting enzyme
[22]. PrP-TM also contains the 3F4 epitope. While wild-type PrP
C
is targeted to DRMs by virtue of both its GPI anchor and lipid raft
targeting determinants in its N-terminal domain, PrP-TM localises
to DRMs solely by means of its N-terminal domain interacting with
raft resident molecule(s) [5]. Thus, PrP-TM offers a unique system
to identify cellular components that interact with the N-terminal
domainofPrP
C and targetittolipid rafts.SH-SY5Y cellsexpressing
PrP-TM were surface biotinylated and then incubated with heparin
prior to DRM isolation. As reported previously [5,24], PrP-TM
resided exclusively in the DRM fractions of the plasma membrane
(Fig. 2A). However, in those cells that had been incubated with
heparin, 44% of PrP-TM was now localised to the detergent-soluble
fractions at the base of the sucrose gradient (Fig. 2A and C). As with
wild type PrP
C, the heparin treatment did not increase the
expression or stability of PrP-TM (Fig. 1E and F). In parallel, SH-
SY5Y cells expressing PrP-TM were incubated with bacterial
phosphatidylinositol-specific phospholipase C (PI-PLC) to deter-
mine whether the lipid raft targeting of PrP-TM was due to raft-
resident GPI-anchored proteins (Fig. 2B). Treatment of cells with
PI-PLC after cell surface biotinylation almost completely abrogated
PrP-TM association with the DRMs but had no effect on the DRM
distribution of flotillin-1 (Fig. 2B and C), indicating that gross
disruption of the rafts had not occurred. One interpretation of the
ability of both exogenous heparin and PI-PLC treatment to inhibit
the association of PrP-TM with DRMs is that a GPI-anchored
HSPG is responsible for the lipid raft targeting of PrP-TM.
The glypicans are a family of GPI-anchored HSPGs [27], of which
glypican-1 is particularly abundant in neurons [28]. To assess whether
glypican-1 is involved in the interaction of PrP-TM with DRMs, SH-
Author Summary
The prion diseases are unique in that their infectious
nature is not dependent on nucleic acid but is instead
attributed to a misfolded protein, the prion protein. This
misfolded prion protein is capable of inducing the
misfolding of the normal form of the prion protein that
is present on the surface of neurons and other cells in the
body. However, the site in the cell at which this misfolding
occurs and whether other proteins are involved remains
controversial. We have addressed these questions by
investigating how the normal form of the prion protein
is targeted to specialised domains on the plasma
membrane termed cholesterol-rich lipid rafts. We show
that targeting is due, in part, to a particular heparin sulfate
proteoglycan called glypican-1. Significantly, reducing the
levels of glypican-1 in an infected cell line reduced the
accumulation of misfolded prion protein. We propose that
glypican-1 acts as a scaffold facilitating the favourable
interaction of the misfolded, infectious form of the prion
protein with the normal cellular form within cholesterol-
rich lipid rafts. Our results indicate that glypican-1 is
intimately involved in the misfolding of the prion protein,
the critical event in the pathogenesis of prion diseases
such as Creutzfeldt-Jakob disease in humans.
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PLoS Pathogens | www.plospathogens.org 2 November 2009 | Volume 5 | Issue 11 | e1000666Figure 1. Heparin stimulates the endocytosis of PrP
C in a dose-dependent manner and displaces it from detergent-resistant lipid
rafts. (A) SH-SY5Y cells expressing PrP
C were surface biotinylated and then incubated for 1 h at 37uC in the absence or presence of various
concentrations of heparin diluted in OptiMEM. Prior to lysis cells were, where indicated, incubated with trypsin to digest cell surface PrP
C. Cells were
then lysed and PrP
C immunoprecipitated from the sample using antibody 3F4. Samples were subjected to SDS PAGE and western blot analysis and
the biotin-labelled PrP
C detected with peroxidase-conjugated streptavidin. (B) Densitometric analysis of multiple blots from four separate
experiments as described in (A) is shown. (C) SH-SY5Y cells expressing PrP
C were surface biotinylated and then incubated in the absence or presence
of 50 mM heparin prepared in OptiMEM for 1 h at 37uC. Cells were homogenised in the presence of 1% (v/v) Triton X-100 and subjected to buoyant
sucrose density gradient centrifugation. PrP
C was immunoprecipitated from equal volumes of each gradient fraction using 3F4 and subjected to SDS-
PAGE and western blotting. The gradient fractions from both the untreated and heparin treated cells were analysed on the same SDS gel and
immunoblotted under identical conditions. The biotin-labelled PrP
C was detected with peroxidase-conjugated streptavidin. Flotillin-1 and transferrin
receptor (TfR) were detected by immunoblotting as markers for DRM and detergent-soluble fractions, respectively. (D) Densitometric analysis of the
proportion of total PrP
C in the detergent soluble fractions of the plasma membrane. (E) Untransfected SH-SY5Y cells and SH-SY5Y cells expressing
either PrP
C or PrP-TM were grown to confluence and then incubated for 1 h in the presence or absence of 50 mM heparin prepared in OptiMEM.
Media samples were collected and concentrated and cells harvested and lysed. Cell lysate samples were immunoblotted for PrP
C using antibody 3F4,
with b-actin used as a loading control. (F) Quantification of PrP
C and PrP-TM levels after treatment of cells with heparin as in (E). Experiments were
performed in triplicate and repeated on three occasions. * P,0.05.
doi:10.1371/journal.ppat.1000666.g001
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PLoS Pathogens | www.plospathogens.org 3 November 2009 | Volume 5 | Issue 11 | e1000666Figure 2. The association of PrP-TM with DRMs is disrupted by treatment of cells with either heparin or bacterial PI-PLC. SH-SY5Y
cells expressing PrP-TM were surface biotinylated and then (A) incubated in the absence or presence of 50 mM heparin prepared in OptiMEM for 1 h
at 37uCo r( B) incubated in the absence or presence of 1 U/ml bacterial PI-PLC for 1 h at 4uC. Cells were homogenised in the presence of 1% (v/v)
Triton X-100 and subjected to buoyant sucrose density gradient centrifugation. PrP-TM was immunoprecipitated from equal volumes of each
gradient fraction using 3F4 and subjected to western blotting. The biotin-labelled PrP-TM fraction was detected with peroxidase-conjugated
streptavidin. Flotillin-1 and transferrin receptor (TfR) were detected by immunoblotting as markers for DRM and detergent-soluble fractions
respectively. (C) Densitometric analysis of the proportion of total PrP-TM present in the detergent soluble fractions of the plasma membrane after
heparin and PI-PLC treatment. Experiments were performed in triplicate and repeated on three occasions. * P,0.05.
doi:10.1371/journal.ppat.1000666.g002
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siRNA or a siRNA pool directed against glypican-1. The specific
siRNAs reduced the amount of glypican-1 in the cells by 84%
(Fig. 3A). The siRNA treated cells were surface biotinylated prior to
DRM isolation. In glypican-1 siRNA treated cells a large proportion
(64%) of PrP-TM was displaced from the DRMs, instead localising
with the detergent-soluble fractions (Fig. 3B and C), indicating that
glypican-1 plays a role in the lipid raft targeting of PrP-TM.
Glypican-1 retains PrP
C in lipid rafts at the cell surface
Next, we sought to determine if glypican-1 was involved in the
lipid raft targeting of wild type PrP
C. We reasoned that if glypican-
1 is involved in the raft targeting of PrP
C, then its depletion should
increase the endocytosis of PrP
C. SH-SY5Y cells expressing PrP
C
were treated with either control siRNA or siRNA against glypican-
1. Cells were then surface biotinylated, incubated for 1 h at 37uC
and the amount of PrP
C endocytosed determined. In those cells
treated with the control siRNA, incubation in serum-free medium
resulted in little detectable endocytosis of PrP
C (Fig. 4A and B).
However, in the cells treated with the glypican-1 siRNA, a modest
but significant amount (19%) of PrP
C was endocytosed (Fig. 4A
and B). In the cells treated with the glypican-1 siRNA, a significant
knockdown (88%) of glypican-1 was clearly apparent, with no
detectable effect on the amount of PrP
C (Fig. 4C).
We also assessed the raft distribution of PrP
C in cells treated
with control or glypican-1 siRNA. Cells were then surface
biotinylated and incubated for 1 h at 37uC in the presence of
tyrphostin A23, to block clathrin-mediated endocytosis [24]. In
Figure 3. Depletion of glypican-1 inhibits the association of PrP-TM with DRMs. SH-SY5Y cells expressing PrP-TM were treated with either
control siRNA or siRNA targeted to glypican-1 and then allowed to reach confluence for 48 h. Cells were subsequently surface biotinylated and
incubated in OptiMEM for 1 h at 37uC in the presence of Tyrphostin A23 to block endocytosis. The media was removed and the cells washed in
phosphate-buffered saline prior to homogenisation in the presence of 1% (v/v) Triton X-100 and subjected to buoyant sucrose density gradient
centrifugation. (A) Quantification of glypican-1 and PrP-TM expression in cell lysates. To detect glypican-1, cell lysate samples were treated with
heparinase I and heparinase III prior to electrophoresis as described in the materials and methods section. (B) PrP-TM was immunoprecipitated from
equal volumes of each gradient fraction using 3F4 and then subjected to western blotting with peroxidase-conjugated streptavidin. Flotillin-1 and
transferrin receptor (TfR) were detected by immunoblotting as markers for DRM and detergent-soluble fractions, respectively. (C) Densitometric
analysis of the proportion of total PrP-TM present in the detergent soluble fractions of the plasma membrane after siRNA treatment from multiple
blots from three independent experiments. * P,0.05.
doi:10.1371/journal.ppat.1000666.g003
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PLoS Pathogens | www.plospathogens.org 5 November 2009 | Volume 5 | Issue 11 | e1000666Figure 4. Depletion of glypican-1 stimulates the endocytosis of PrP
C. SH-SY5Y cells expressing wild type PrP
C were treated with either
control or glypican-1 siRNA and then incubated for 60 h. Cells were surface biotinylated and incubated in OptiMEM for 1 h at 37uC. Where indicated,
cells were treated with trypsin to remove remaining cell surface PrP
C. Cells were then lysed and total PrP
C immunoprecipitated from the sample using
antibody 3F4. (A) Samples were subjected to western blot analysis and the biotin-labelled PrP
C fraction was detected with peroxidase-conjugated
streptavidin. (B) Densitometric analysis (mean 6 s.e.m.) of multiple blots from three separate experiments in (A) is shown. (C) Expression of glypican-
1 (in lysate samples treated with heparinase I and heparinase III) and PrP
C in the cell lysates from (A). b-actin was used as a loading control. (D) SH-
SY5Y cells expressing PrP
C were treated with either control siRNA or glypican-1 siRNA and then allowed to reach confluence for 48 h. Cells were
subsequently surface biotinylated and incubated in OptiMEM for 1 h at 37uC. Cells were homogenised in the presence of 1% (v/v) Triton X-100 and
subjected to buoyant sucrose density gradient centrifugation. (E) Densitometric analysis of the proportion of total PrP
C present in the detergent
soluble fractions of the plasma membrane after siRNA treatment from three independent experiments. (F) SH-SY5Y cells expressing PrP
C were seeded
onto glass coverslips and grown to 50% confluency. Cells were fixed, and then incubated with anti-PrP antibody 3F4 and a glypican-1 polyclonal
antibody. Finally, cells were incubated with Alexa488-conjugated rabbit anti-mouse and Alexa594-conjugated goat anti-rabbit antibodies and viewed
using a DeltaVision Optical Restoration Microscopy System. Images are representative of three individual experiments. Scale bars equal 10 mm.
*P ,0.05.
doi:10.1371/journal.ppat.1000666.g004
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C resided exclusively in
the DRMs (Fig. 4D). In contrast, in cells treated with glypican-1
siRNA a significant amount (20.6%) of cell surface PrP
C localised
to the detergent-soluble fractions of the sucrose gradient (Fig. 4D
and E). Immunofluorescence microscopy revealed that PrP
C and
glypican-1 extensively colocalised on the surface of the cells
(Fig. 4F). Collectively these data indicate that PrP
C and glypican-1
co-localise on the cell surface and that knockdown of glypican-1
allows PrP
C to translocate out of the detergent-insoluble rafts into




Sc interact with glypican-1
We next sought to determine if glypican-1 is able to interact
directly with PrP
C and PrP
Sc by co-immunoprecipitation. When
cell lysates prepared using Triton X-100 from SH-SY5Y cells
stably expressing PrP
C (Fig. 5A) or N2a cells endogenously
expressing PrP
C (Fig. 5B) were incubated with a polyclonal
antibody against glypican-1, PrP
C was co-immunoprecipitated in
both cases (Fig. 5A). The interaction between glypican-1 and PrP
C
was disrupted by prior treatment of the cell lysates with heparinase
I and heparinase III to digest the heparan sulfate chains on
glypican-1 [29,30] or exogenous heparin (Fig. 5A and B),
indicating that the interaction between PrP
C and glypican-1
involves the heparan sulfate sidechains on the latter. In order to
provide further evidence that glypican-1 and PrP
C are directly
associated, co-immunoprecipitation experiments were performed
using cells lysed with sarkosyl or octylglucoside, detergents known
to completely solubilise lipid rafts [31–33]. PrP
C co-immunopre-
cipitated with glypican-1 using lysates prepared with either
detergent (Fig. 5A and B).
To address whether glypican-1 was also able to interact with
PrP
Sc we performed co-immunoprecipitation experiments using
cell extracts prepared from mouse neuroblastoma cells persistently
infected with PrP
Sc (ScN2a cells). Immunoprecipitation of
glypican-1 led to the co-immunoprecipitation of PrP from cells
lysed with either Triton X-100 or octylglucoside (Fig. 5C).
Sarkosyl is unsuitable for use in co-immunoprecipitation experi-
Figure 5. PrP
C and PrP
Sc immunoprecipitate with glypican-1. (A) SH-SY5Y cells expressing PrP
C,( B) N2a cells or (C and D) ScN2a cells were
lysed in the indicated detergents and then immunoprecipitated with a polyclonal glypican-1 antibody and where indicated, co-incubated with 50 mM
heparin. Those samples pretreated with heparinase I and heparinase III were lysed with Triton X-100 followed by immunoprecipitation with glypican-
1 antibody. In (D), immunopreciptiates from ScN2a cells were digested with PK. All immunoprecipitates were subsequently blotted for PrP. TX, Triton
X-100; OG, octylglucoside; SK, sarkosyl.
doi:10.1371/journal.ppat.1000666.g005
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Sc [34].
Co-immunoprecipitation of PrP with glypican-1 in Triton-
extracted cells was inhibited by co-incubation with exogenous
heparin or removal of the heparan sulfate sidechains on glypican-1
with heparinase I and heparinase III treatment (Fig. 5C). When
the protein A-sepharose pellets were treated with proteinase K
(PK) prior to subsequent analysis, PrP
Sc was found to have
precipitated with glypican-1 in both the Triton X-100 and
octylglucoside extracted cells (Fig. 5D). Similarly, the interaction
between glypican-1 and PrP
Sc was inhibited by addition of
exogenous heparin to the cell lysates or pre-treatment of samples
with heparinase I and heparinase III (Fig. 5D). These data indicate
that glypican-1 is capable of interacting via its heparan sulfate
chains with both normal and protease-resistant forms of PrP.
Depletion of glypican-1 inhibits the formation of PrP
Sc
Next we investigated if the interaction with glypican-1 could
modulate the conversion of PrP
C to PrP
Sc. ScN2a cells were
treated with the control siRNA or one of four siRNA duplexes
targeted to mouse glypican-1. After a total incubation period of
96 h, cells were harvested, lysed, and then the cell lysates digested
with PK prior to SDS-PAGE and subsequent immunoblotting
(Fig. 6A). Treatment with the control siRNA did not alter the level
of PK-resistant PrP
Sc. However, in cells treated with each of the
four glypican-1 siRNA duplexes an average 50% reduction in PK-
resistant PrP
Sc was consistently observed (Fig. 6A and B).
Knockdown (78–87%) of glypican-1 by the siRNA duplexes in
the ScN2a cells was confirmed by immunoblotting (Fig. 6C). The
reduction in PK-resistant PrP
Sc seen in the glypican-1 depleted
cells was not a consequence of a more general reduction in PrP
levels, as when non-PK digested samples were immunoblotted the
amount of total PrP was unaltered relative to the control siRNA
treated cells (Fig. 6C).
Next we sought to confirm the specificity of glypican-1 in
modulating the conversion of PrP
C to PrP
Sc by testing whether
another HSPG, syndecan-1, could influence PrP
Sc accumulation
in ScN2a cells. When cells were treated with syndecan-1 siRNA
over an incubation period of 96 h, the level of PK-resistant PrP
Sc
remained comparable to control siRNA treated cells (Fig. 6D and
E). In contrast, treatment of ScN2a cells with glypican-1 siRNA
once more led to 50% reduction in PK-resistant PrP
Sc (Fig. 6D
and E). Knockdown of glypican-1 (73.365.3%) and syndecan-1
(60.766.3%) was confirmed by immunoblotting (Fig. 6F).
Cell division can modulate the accumulation of prions in ScN2a
cells [35] and glypican-1 depletion has been reported to inhibit cell
proliferation in endothelial cells by arresting cell cycle progression
[36]. Therefore, we investigated whether the effect of glypican-1
knockdown was altering the amount of PrP
Sc in the ScN2a cells due
to modulation of cell division. However, glypican-1 depletion did
not significantly affect cell proliferation compared to mock-treated
and control siRNA-treated cells (Fig. 7A). As the cell surface is the
probable site for the initial interaction between the two isoforms of
PrP[11],weassessed whether the reductioninPrP
Scassociated with
glypican-1depletionwasduetoanalterationinthe steadystate level
of PrP at the cell surface. ScN2a cells were surface biotinylated
followingtreatmentwith eithercontrolsiRNAorglypican-1siRNA.
Although there was a reduction in the amount of PrP
Sc in the
glypican-1 siRNA treated cells, there was no difference in the
amount of biotinylated cell surface PrP (Fig. 7B and C).
Glypican-1 is not involved in the inhibitory effect of PrP
C
on the BACE1 cleavage of APP
We have recently reported that PrP
C inhibits the cleavage of the
amyloid precursor protein (APP) by the b-secretase BACE1 [19].
This effect was dependent on the lipid raft localisation of PrP
C and
was mediated by the N-terminal polybasic region of PrP
C through
interaction with GAGs [19]. Therefore, we hypothesised that
glypican-1 may be involved in the mechanism by which PrP
C
regulates the BACE1 cleavage of APP. To address this, control
siRNA or siRNA directed against glypican-1 were transfected into
SH-SY5Y cells expressing PrP
C. Parallel experiments were
performed in SH-SY5Y cells transfected with an empty pIRESneo
vector. In the media from control siRNA-treated cells expressing
PrP
C the level of sAPPb, the product of BACE1 cleavage of APP,
was dramatically reduced relative to cells lacking PrP
C (Fig. 8A
and B), as seen previously [19]. In media from the empty vector
cells treated with glypican-1 siRNA there was no alteration in the
level of sAPPb relative to control siRNA-treated cells (Fig. 8A and
B). Significantly, levels of sAPPb in the cells expressing PrP that
had been treated with the glypican-1 siRNA were not altered
relative to the control siRNA treated cells (Fig. 8A and B),
implying that the GAG sidechains of glypican-1 are not critical in
mediating the inhibition of BACE1 by PrP
C.
Discussion
By utilising a transmembrane anchored form of PrP, PrP-TM,
which associates with DRMs solely by means of its N-terminal
domain and not also via the GPI anchor as in wild type PrP
C,w e
have identified the GPI-anchored HSPG, glypican-1, as involved
in targeting PrP
C to detergent-resistant lipid rafts in the plasma
membrane of neuronal cells. Furthermore, we have shown that
depletion of glypican-1 by siRNA knock down significantly inhibits
the formation of PrP
Sc in a scrapie-infected cell line. Thus, we
have identified glypican-1 as a novel cofactor involved in the
cellular conversion of PrP
C to PrP
Sc. Glypican-1 appeared to be
interacting via its heparan sulfate chains with both PrP
C and
PrP
Sc, as the interaction was inhibited by digestion of its GAG
chains with heparinase I and heparinase III. This would be
consistent with a previous study, where treatment of ScN2a cells
with heparinase III caused a profound reduction in the level of
PrP
Sc [37].
We propose a model where glypican-1 acts as a scaffold for
prion propagation by binding to both PrP
C and PrP
Sc, thereby
bringing them into close enough proximity within lipid rafts to
facilitate prion conversion (Fig. 9A). This is supported by the
observation that both PrP
C and PrP
Sc co-immunoprecipitated with
glypican-1 and that both isoforms of PrP are localised in lipid rafts
[6,7]. Glypican-1 may be acting as a catalyst, increasing the rate of
conversion of PrP
C to PrP
Sc. In this respect, a previous study has
demonstrated that pentosan polysulfate destabilised protease-
sensitive PrP with a loss of a-helical structure [38]. Thus, a
potential mechanism by which glypican-1 may be acting is
through its heparan sulfate side chains exerting a similar
destabilising effect on the structural stability of PrP
C, thereby
facilitating its refolding in the presence of PrP
Sc. Although
depletion of glypican-1 did not alter the cell surface level of PrP,
we cannot exclude the possibility that glypican-1 may also have an
effect on the conversion of PrP
C to PrP
Sc by altering the trafficking
or clearance of PrP
Sc.
Glypican-1 itself is internalised from the plasma membrane by a
mechanism involving caveolin-1 [39]. During its intracellular
trafficking the heparin sulfate chains of glypican-1 are removed
and degraded, either by heparanase cleavage or a non-enzymatic
deaminative cleavage which is nitric oxide-catalysed and Cu
2+-/
Zn
2+-dependent [40]. The nitric oxide is derived from nitrosylated
cysteine residues within the glypican-1 core protein, formed via a
Cu
2+-dependent redox reaction [41]. In both cell-free experiments
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Sc formation. ScN2a cells were either untreated or incubated with either control
siRNA or one of four siRNAs targeted to glypican-1. After 48 h incubation the treatments were repeated. After a total incubation period of 96 h cells
were harvested, lysed and protein concentration determined. (A) For detection of PK-resistant PrP
Sc, samples containing 200 mg protein were
digested with 4 mg PK for 30 min at 37uC. Protein was then recovered by methanol precipitation and immunoblotted for PrP using antibody 6D11.
(B) Densitometric analysis (mean 6 s.e.m.) of PK-resistant PrP
Sc levels for each treatment, relative to those of mock-treated cells, from multiple blots
from four independent experiments. (C) To confirm that glypican-1 depletion had been achieved in the ScN2a cells, cell lysate samples were
immunoblotted for glypican-1, as well as PrP and b-actin. (D) To confirm the specificity of glypican-1 in modulating PrP
Sc formation, ScN2a cells were
treated with control, syndecan-1 or glypican-1 siRNA reagents. Samples were processed as described in (A). (E) Densitometric analysis (mean 6 s.e.m.)
of PK-resistant PrP
Sc levels for each treatment in (D), from multiple blots from three independent experiments. (F) Confirmation of syndecan-1 and
glypican-1 knockdown by immunblotting.
doi:10.1371/journal.ppat.1000666.g006
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2+-loaded PrP
C was shown to support the
nitrosylation of glypican-1 [40]. Recently, it was proposed that
glypican-1 autoprocessing is involved in the cellular clearance of
PrP
Sc [42]. These authors used scrapie-infected hypothalamic
(ScGT1) cells and immunofluorescence microscopy to show that
PrP
Sc-associated immunofluorescence was increased in cells
treated with a glypican-1 specific siRNA, though no direct
quantification was provided [42]. In addition, when ScGT1 cells
were treated with reagents to inhibit glypican-1 autoprocessing,
western blot analysis revealed increased levels of PrP
Sc [42]. From
this, these authors argued that glypican-1 autoprocessing may
contribute to the cellular clearance of PrP
Sc, thus inhibiting this
process would lead to an increase in PrP
Sc accumulation [42].
However, prevention of the autoprocessing of glypican-1 may
increase the half-life of the protein, and thus lead to the observed
rise in PrP
Sc if glypican-1 is a cofactor in prion conversion as our
data indicate.
Interestingly, PrP
Sc still propagated following the substantial
knock down of glypican-1 by siRNA; PrP
Sc levels were reduced by
at most 55% despite glypican-1 protein levels being reduced by
over 80%. One possibility is that the remaining glypican-1 is
sufficient to support prion conversion. Alternatively, these data
may be interpreted with respect to the protein-only hypothesis in
that PrP
Sc is sufficient on its own to convert PrP
C, with glypican-1
acting merely as a catalyst [1]. Another possibility is the existence
of other conversion-favouring cellular cofactors, which may
include other HSPGs although the lack of effect of syndecan-1
depletion on PrP
Sc formation argues against the involvement of
this family of proteoglycans. In this context it is also interesting to
note that siRNA knock down of glypican-1 did not completely
abolish the association of PrP-TM with DRMs, suggesting the
existence of additional lipid raft targeting molecules. Such
components may be proteins, such as other members of the
glypican family [27] or lipids. In support of the latter, PrP lacking
its GPI anchor was shown to interact with cholesterol and
sphingomyelin containing raft-like lipid vesicles [4]. Whether the
same additional molecules involved in the raft targeting of PrP
C
are also involved in facilitating the conversion of PrP
C to PrP
Sc
Figure 7. Depletion of glypican-1 does not affect cell division or surface levels of PrP
C. (A) ScN2a cells were seeded into 96 well plates and
treated with transfection reagent only or incubated with either control siRNA or one of the four siRNAs targeted to glypican-1. Those experiments
exceeding 48 h were dosed with a second treatment of the indicated siRNAs. Cells were then rinsed with PBS and fixed with 70% (v/v) ethanol. Plates
were allowed to dry, stained with Hoescht 33342 and the fluorescence measured. (B) ScN2a cells were treated with control or glypican-1 siRNA. After
96 h, cell monolayers were labelled with a membrane impermeable biotin reagent. Biotin-labelled cell surface PrP was detected by
immunoprecipitation using 6D11 and subsequent immunoblotting using HRP-conjugated streptavidin. Total PrP and PK-resistant PrP (PrP
Sc) were
detected by immunoblotting using antibody 6D11. (C) Densitometric analysis of the proportion of the relative amount of biotinylated cell surface PrP
in the absence or presence of glypican-1 siRNA from three independent experiments.
doi:10.1371/journal.ppat.1000666.g007
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role in these processes.
To our knowledge the only other protein to date shown to be
capable of influencing prion accumulation in cultured cells is the
37 kDa/67 kDa laminin receptor [43]. When infected cells were
depleted of the 37 kDa/67 kDa laminin receptor, PrP
Sc levels were
significantly reduced, although this may be the result of reduced
PrP
C expression seen after these treatments rather than the loss of a
direct role for the 37 kDa/67 kDa laminin receptor in prion
conversion [43]. Interestingly, PrP
C interacted with the 37 kDa/
67 kDa laminin receptor via both a direct interaction involving
residues 144–179 and an indirect interaction via an unidentified
HSPG involvingresidues53–93ofPrP
C [44].Whetherglypican-1is
this intermediate HSPG awaits further study.
Like heparan sulfate, many of the anti-prion compounds
identified to date are, or have the capacity to stack into, large
polyanionic chains [45]. This suggests a common mechanism of
inhibition of PrP
Sc accumulation by these compounds, perhaps by
binding to the same or overlapping sites on PrP. In support of this,
sulfated glycans have been shown to compete with both Congo red
and phosphorothioated oligonucleotides for binding to PrP
C
[46,47]. It is possible that some of the anti-prion compounds
identified to date exert their effects by antagonising the binding of
glypican-1 to PrP
C and PrP
Sc. The ability of exogenous heparin to
inhibit the co-immunoprecipitation of glypican-1 with both PrP
C
and PrP
Sc supports such a hypothesis. Thus, such anti-prion
compounds may directly disrupt the interaction between PrP
C/
PrP
Sc and glypican-1 which is required for optimal prion
conversion. Alternatively, the observation that heparin promotes
the endocytosis of PrP
C, may suggest that some anti-prion
compounds could act by a similar mechanism, promoting the
endocytosis of PrP
C, thereby directing the protein to late endosomes
and/or lysosomes where conversion to PrP
Sc is inefficient [15] and/
or removing PrP
C from the cell surface lipid rafts where glypican-1
facilitates conversion. Following from these results, the design of
specific small molecule inhibitors to antagonise the binding of
glypican-1 and PrP
C/PrP
Sc may represent a viable therapeutic
avenue for the treatment of prion diseases. With any potential
treatment for prion diseases that targets PrP
C, there is the concern
that the normal functions of the protein may be adversely affected.
Inthisrespect,thelackofeffectofglypican-1depletionontheability
of PrP
C to inhibit the cleavage of APP by BACE1 [19] suggests that
at least one of the proposed physiological functions of PrP
C [48] is
independent of its interaction with glypican-1.
Although heparan and other GAGs disrupt prion conversion in
both cell and animal models [49–54], such compounds stimulate
the conversion of PrP
C to PrP
Sc in cell free systems [38,55]. From
our data this apparent paradox can be explained by exogenous
GAGs competitively inhibiting the binding of PrP
C/PrP
Sc to
glypican-1 in the cell and animal models, thus not allowing the
cellular and infectious forms of PrP to come into close enough
contact for conversion to occur (Fig. 9B). While in the cell-free
systems the GAGs provide a scaffold to promote the interaction of
PrP
Sc with PrP
C thereby facilitating conversion.
In conclusion, we have identified the cell surface HSPG,
glypican-1, as a novel lipid raft targeting determinant for PrP
C.I n
addition, we show that depletion of glypican-1 inhibits the
formation of PrP
Sc in scrapie-infected cells, implying that
glypican-1 is a novel cellular cofactor in prion conversion.
Furthermore, we show that glypican-1 is not required for one of
the proposed physiological functions of PrP
C, inhibition of the b-
secretase cleavage of APP.
Materials and Methods
PrP constructs and cell culture
Insertion of the coding sequence of murine PrP containing a 3F4
epitope tag into pIRESneo (Clontech-Takara Bio Europe) and
generation of the PrP-TM construct have been reported previously
[22]. For stable transfection of the cDNA encoding the PrP
constructs, 30 mg DNA was introduced into human SH-SY5Y
Figure 8. Depletion of glypican-1 does not affect the inhibition
of BACE1 by PrP
C. SH-SY5Y cells co-expressing APP695 and PrP or
cells expressing APP695 and an empty pIRESneo vector were treated
with control siRNA or siRNA targeted to glypican-1. After 30 h the
medium was replaced and cells incubated with reduced-serum medium
for a further 24 h. Conditioned medium was harvested and cell lysates
prepared. (A) Expression of glypican-1, full-length APP and PrP
C in cell
lysates, with b-actin as a loading control. Immunodetection of sAPPb in
conditioned medium. (B) Densitometric analysis of sAPPb levels in
glypican-1 depleted cells relative to control siRNA cells, calculated from
multiple blots from three independent experiments.
doi:10.1371/journal.ppat.1000666.g008
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in normal growth medium containing G418 selection antibiotic.
Mouse N2a neuroblastoma cells, N2a cells infected with the mouse-
adapted 22L scrapie strain (ScN2a) [56] and SH-SY5Y cells were
routinely cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% foetal bovine serum, 50 U/ml penicillin and
0.1 mg/ml streptomycin (all from Invitrogen). Cells were maintained
in a humidified incubator at 37uC with 5% CO2. For analysis of cell-
associated proteins, cells were washed with phosphate-buffered saline
(20 mM Na2HPO4, 2 mM NaH2PO4, 0.15 M NaCl, pH 7.4) and
scraped from the flasks into phosphate-buffered saline. Cells were
pelleted by centrifugation at 500 g for 5 min. Unless indicated
otherwise, pelleted cells were lysed in ice cold lysis buffer (150 mM
NaCl, 0.5% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate,
50 mM Tris-HCl, pH 7.5) supplemented with a complete protease
inhibitor cocktail (Roche Applied Science, Burgess Hill, U.K).
Endocytosis assay
Cells at confluency were incubated for 1 h at 4uC with 0.5 mg/
ml Biotin sulfo-NHS (Sigma-Aldrich, Poole, U.K.). Cells were then
incubated for 30 min at 37uC in OptiMEM. Prior to cell lysis, PrP
remaining on the cell surface was removed by digestion with
trypsin as described previously [23,24].
DRM isolation
Cells at confluence were surface biotinylated and then treated as
described in individual experiments in the presence of Tyrphostin
A23 to prevent PrP
C endocytosis [24]. Media was then removed
and cells rinsed in phosphate-buffered saline. Cells were
subsequently harvested and then resuspended in Mes-buffered
saline (25 mM Mes, 150 mM NaCl, pH 6.5) containing 1% (v/v)
Triton X-100. Cells were then homogenised by passing through a
Luer 21-gauge needle. After centrifugation at 500 g for 5 min to
pellet cell debris, the supernatant was harvested and made 40%
(v/v) with respect to sucrose by addition of an equal volume of
80% (v/v) sucrose. A 1 ml aliquot of the sample was then placed
beneath a discontinuous sucrose gradient comprising 3 ml of 30%
sucrose and 1 ml of 5% sucrose, both in Mes-buffered saline. The
samples were centrifuged at 140,000 g in an SW-55 rotor
(Beckman Coulter Inc., CA, U.S.A.) for 18 h at 4uC. The sucrose
gradients were harvested in 0.5 ml fractions from the base of the
gradient and the distribution of proteins monitored by western blot
analysis of the individual fractions. Where indicated, biotin-
labelled PrP was detected by subsequent immunoprecipitation of
epitope-tagged PrP from the individual fractions using antibody
3F4 (Eurogentec Ltd., Southampton, U.K.) and subsequent
immunoblotting using horseradish peroxidase-conjugated strepta-
vidin (Thermo Fisher Scientific, Cramlington, U.K.).
Protein assay and enzyme treatments
Protein was quantified using bicinchoninic acid [57] in a
microtitre plate-based assay using bovine serum albumin as
standard. To detect PK-resistant PrP
Sc, cell lysate samples
containing 200 mg of protein in a total volume of 200 ml were
Figure 9. Proposed model for glypican-1 in prion conversion. Under normal circumstances, glypican-1 (light grey) with its heparan sulfate
side chains (black lines) constitutes a lipid raft targeting determinant for PrP
C.( A) For PrP
C (dark grey) to exit lipid rafts and undergo endocytosis
through its interaction with low density lipoprotein receptor-related protein 1 (LRP1, thick black line [59]), its interaction with glypican-1 mustb e
disrupted (arrow 1). In prion disease, we hypothesise that glypican-1 provides a scaffold to facilitate interaction between PrP
C and PrP
Sc (chequered)
and allow misfolding of PrP
C to proceed (arrow 2). (B) Prion therapeutic strategies may act, in part, by disrupting the interaction of PrP
C and PrP
Sc that
is facilitated through the heparan sulfate sidechains of glypican-1.
doi:10.1371/journal.ppat.1000666.g009
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terminated by the addition of phenylmethanesulfonyl fluoride to a
final concentration of 3 mM. Protein in the samples was
precipitated by the addition of 800 ml of ice cold methanol and
incubated overnight at 4uC. Precipitated protein was pelleted by
centrifugation andthen resuspended indissociationbuffer(125 mM
Tris-HCl pH 8.0, 2% (w/v) sodium dodecyl sulfate, 20% (v/v)
glycerol, 100 mM dithiothreitol, bromophenol blue, pH 6.8) prior
to SDS-PAGE. To remove heparan sulfate sidechains from HSPGs
prior to detection of glypican-1 and syndecan-1 core proteins by
immunoblotting, cell lysates (50 mg protein) were incubated for 5 h
at 37uC in the presence of 1 m unit heparinase I and 1 m unit
heparinase III (both Sigma). To remove cell surface GPI-anchored
proteins, cell monolayers were incubated for 1 h at 4uC with 1 U/
ml Bacillus thuringiensis phosphatidylinositol-specific phospholipase C
(PI-PLC) (Sigma-Aldrich).
SDS-PAGE and western blot analysis
Samples were prepared in dissociation buffer and boiled for
5 min. Proteins were resolved by SDS-PAGE using either 7–17%
polyacrylamide gradient gels or 14.5% polyacrylamide gels. For
western blot analysis, resolved proteins were transferred to
Immobilon P polyvinylidene difluoride membrane (Amersham,
Little Chalfont, U.K.). The membrane was blocked by incubation
for 1 h with phosphate-buffered saline containing 0.1% (v/v)
Tween-20 and 5% (w/v) dried milk powder. Antibody incubations
wereperformed inphosphate-bufferedsaline-Tween containing2%
(v/v) bovine serum albumin. Antibody 3F4 recognises the 3F4
epitope tag (corresponding to amino acid residues 109–112 of
human PrP) at residues 108–111 of the chimeric murine PrP and
was used at a dilution of 1:4000; antibody 6D11 (Eurogentec Ltd.)
recognises an epitope within amino acids 93–109 of PrP and was
used at 1:10000; antibody 22C11 (Millipore (UK) Ltd, Livingston,
U.K.) recognises amino acid residues 66–81 at the N-terminus of
APP and was used at 1:2500; antibody 1A9 (GlaxoSmithKline,
Harlow, U.K.) recognises a neoepitope on the soluble ectodomain
fragmentofAPP derivedfromb-secretasecleavage(sAPPb)andwas
used at 1:2500; antibody S1 against human glypican-1 was a kind
gift from Professor G. David (Flanders Institute for Biotechnology,
Belgium) and was used at 1:2000; polyclonal anti-glypican-1 and
anti-syndecan-1 (both Abcam plc, Cambridge, U.K.) were used at
1:1000; and anti-actin antibody (Sigma) at 1:5000. Horseradish
peroxidase-conjugated streptavidin was used at 1:2000. Bound
antibody was detected using peroxidase-conjugated secondary
antibodies in conjunction with the enhanced chemiluminescence
detection method (Amersham Biosciences, Amersham, U.K.).
RNA interference studies
SH-SY5Y cells expressing PrP
C were seeded into T80 flasks at
70%confluencyand incubatedwith500 pmolofa2 mMSmartpool
siRNA solution against glypican-1 or a control Smartpool reagent
(Dharmacon Inc., Chicago, U.S.A.) complexed with Dharma-
FECT-1 transfection regent (Dharmacon Inc.) in serum-free
medium. After 4 h, serum was added to 10% (v/v). Cells were
then incubated for a further 44 h prior to experimentation. To
analyse the role of glypican-1 in the inhibitory action of PrP
C on the
BACE1 cleavage of APP, SH-SY5Y cells expressing APP695 were
transfected with the cDNA encoding PrP
C or an empty pIRESneo
vector and treated with glypican-1 or control Smartpool reagents.
After 30 h the medium was changed to OptiMEM (Invitrogen), and
the cells incubated for a further 24 h. Cells were pelleted and the
medium harvested and centrifuged at 1000 g for 5 min to remove
residual cell debris. Medium was then concentrated 50-fold using
Vivaspin centrifugal concentrators (10 000 MW cut off). To assess
the role of glypcian-1 on prion conversion ScN2a cells were treated
with 500 pmol of the following 2 mM siRNA solutions: Smartpool
glypican-1 solution; one of four individual duplexes targeted to
glypican-1; Smartpool syndecan-1 solution or control Smartpool
siRNA reagent. Cells were treated twice over a 96 h period with
siRNA (at 0 and 48 h). After 96 h cells were harvested and lysed.
Co-immunoprecipitation
Co-immunoprecipitation of PrP isoforms and glypican-1 were
performed as described previously [58]. Briefly, SH-SY5Y cells
expressing PrP
C, N2a cells or ScN2a cells were grown to
confluence and then harvested. Cells were lysed using chilled
immunoprecipitation lysis buffer (150 mM NaCl, 10 mM EDTA,
10 mM KH2PO4, pH 7.5) containing, where indicated 2% (v/v)
Triton X-100, 1% n-octyl-b-D-glucopyranoside (octyl glucoside) or
1% N-laurylsarcosine (sarkosyl). Cell debris were removed by
centrifugation and then lysates precleared for 30 min with 0.5%
(w/v) protein A-Sepharose. The protein A-Sepharose was
removed by centrifugation and the supernatant incubated
overnight at 4uC with anti-PrP antibody (6H4) or anti-glypican-
1 antibody. Protein A-Sepharose was added to 0.5% (w/v) to the
samples and incubation proceeded at 37uC for 1 h. Immunocom-
plexes were pelleted and the pellet washed six times with 150 mM
NaCl, 10 mM Tris-HCl, pH 7.4 containing 0.2% (v/v) Tween-20.
Immunofluorescence microscopy
Cells were seeded onto coverslips and grown to 50% confluency.
Cells were then fixed with 4% (v/v) paraformaldehyde/0.1% (v/v)
glutaraldehyde in PBS for 15 min, and then blocked for 1 h in PBS
containing 5% (v/v) fish skin gelatin (Sigma-Aldrich). Coverslips
were then incubated with anti-PrP antibody 3F4 and anti-glypican-
1 antibody. Finally, coverslips were incubated with the appropriate
fluorescent probe-conjugated secondary antibodies (Molecular
Probes, Eugene, U.S.A.) for 1 h and mounted on slides using
fluoromount G mounting medium (SouthernBiotech, Alabama,
U.S.A). Cells were visualised using a DeltaVision Optical
Restoration Microscopy System (Applied Precision Inc., Washing-
ton, USA). Data were collected from 30–40 0.1 mm thick optical
sections, and 3-D datasets were deconvolved using the softWoRx
programme (Applied Precision Inc.). The presented images
represent individual Z-slices taken from the middle of the cell.
Assessment of cell number by Hoescht 33342 staining
ScN2a cells (1610
4 per well) in 96-well tissue culture plates were
cultured overnight in complete medium. After 24 h, cells were
treated with the indicated siRNA duplexes. Cells were fixed in
70% ethanol at room temperature for 5 min, and the adherent cell
monolayers were stained with the DNA-binding fluorochrome
Hoescht 33342 (8.8 mM). Once dry, the fluorescence of each well
was measured on a Synergy HT (Bio-Tek) fluorescent plate reader
(350 nm excitation and 450 nm emission wavelengths) in order to
determine the cell number in each well.
Statistical analysis
Data are expressed as means (6 s.e.m.). Experiments were
performed in triplicate and repeated on at least three occasions.
Statistical analysis was performed using student’s t-test. P-values
,0.05 were taken as statistically significant.
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